Toll Free: 1-888-928-9744
Published: Sep, 2014 | Pages:
30 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
PsychoGenics, Inc. - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'PsychoGenics, Inc. - Product Pipeline Review - 2014', provides an overview of the PsychoGenics, Inc.'s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of PsychoGenics, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of PsychoGenics, Inc. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of PsychoGenics, Inc.'s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the PsychoGenics, Inc.'s pipeline products Reasons to buy - Evaluate PsychoGenics, Inc.'s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of PsychoGenics, Inc. in its therapy areas of focus - Identify new drug targets and therapeutic classes in the PsychoGenics, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of PsychoGenics, Inc. and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of PsychoGenics, Inc. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of PsychoGenics, Inc. and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 PsychoGenics, Inc. Snapshot 5 PsychoGenics, Inc. Overview 5 Key Information 5 Key Facts 5 PsychoGenics, Inc. - Research and Development Overview 6 Key Therapeutic Areas 6 PsychoGenics, Inc. - Pipeline Review 8 Pipeline Products by Stage of Development 8 Pipeline Products - Monotherapy 9 Pipeline Products - Partnered Products 10 Partnered Products/Combination Treatment Modalities 11 Pipeline Products - Out-Licensed Products 12 Out-Licensed Products/Combination Treatment Modalities 13 PsychoGenics, Inc. - Pipeline Products Glance 14 PsychoGenics, Inc. - Early Stage Pipeline Products 14 IND/CTA Filed Products/Combination Treatment Modalities 14 Preclinical Products/Combination Treatment Modalities 15 Discovery Products/Combination Treatment Modalities 16 PsychoGenics, Inc. - Drug Profiles 17 SEP-360 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 PGI-02776 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 Sazetidine-A 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 Small Molecule to Antagonize Adenosine Receptor for Parkinson's disease 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 Small Molecules for Neuropsychiatric Disorders 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 Small Molecules for Undisclosed Indication 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 PsychoGenics, Inc. - Pipeline Analysis 24 PsychoGenics, Inc. - Pipeline Products by Target 24 PsychoGenics, Inc. - Pipeline Products by Molecule Type 25 PsychoGenics, Inc. - Pipeline Products by Mechanism of Action 26 PsychoGenics, Inc. - Recent Pipeline Updates 27 PsychoGenics, Inc. - Locations And Subsidiaries 28 Head Office 28 Appendix 29 Methodology 29 Coverage 29 Secondary Research 29 Primary Research 29 Expert Panel Validation 29 Contact Us 30 Disclaimer 30
List of Tables PsychoGenics, Inc., Key Information 5 PsychoGenics, Inc., Key Facts 5 PsychoGenics, Inc. - Pipeline by Indication, 2014 7 PsychoGenics, Inc. - Pipeline by Stage of Development, 2014 8 PsychoGenics, Inc. - Monotherapy Products in Pipeline, 2014 9 PsychoGenics, Inc. - Partnered Products in Pipeline, 2014 10 PsychoGenics, Inc. - Partnered Products/ Combination Treatment Modalities, 2014 11 PsychoGenics, Inc. - Out-Licensed Products in Pipeline, 2014 12 PsychoGenics, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2014 13 PsychoGenics, Inc. - IND/CTA Filed, 2014 14 PsychoGenics, Inc. - Preclinical, 2014 15 PsychoGenics, Inc. - Discovery, 2014 16 PsychoGenics, Inc. - Pipeline by Target, 2014 24 PsychoGenics, Inc. - Pipeline by Molecule Type, 2014 25 PsychoGenics, Inc. - Pipeline Products by Mechanism of Action, 2014 26 PsychoGenics, Inc. - Recent Pipeline Updates, 2014 27
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.